(Q36544077)

14 August 2017

Comprehensive investigation of oncogenic driver mutations in Chinese non-small cell lung cancer patients (English)

1 reference

14 August 2017

1 reference

Rui Wang

1

1 reference

14 August 2017

Yang Zhang

2

1 reference

14 August 2017

Yunjian Pan

3

1 reference

14 August 2017

Yuan Li

4

1 reference

14 August 2017

Haichuan Hu

5

1 reference

14 August 2017

Deng Cai

6

1 reference

14 August 2017

Hang Li

7

1 reference

14 August 2017

Ting Ye

8

1 reference

14 August 2017

Xiaoyang Luo

9

1 reference

14 August 2017

Yiliang Zhang

10

1 reference

14 August 2017

Bin Li

11

1 reference

14 August 2017

Lei Shen

12

1 reference

14 August 2017

Yihua Sun

13

1 reference

14 August 2017

Haiquan Chen

14

1 reference

14 August 2017

language of work or name

English

0 references

publication date

12 October 2015

1 reference

14 August 2017

1 reference

14 August 2017

6

1 reference

14 August 2017

33

1 reference

14 August 2017

34300-34308

1 reference

Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs

14 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4741453

Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4741453

CD74-NRG1 fusions in lung adenocarcinoma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4741453

Novel germline mutation in the transmembrane domain of HER2 in familial lung adenocarcinomas.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4741453

The somatic genomic landscape of glioblastoma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4741453

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4741453

Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4741453

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4741453

Oncogenic ERBB3 mutations in human cancers

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4741453

Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4741453

Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4741453

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4741453

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4741453

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4741453

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4741453

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4741453

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4741453

Druggable oncogene fusions in invasive mucinous lung adenocarcinoma.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4741453

FGFR1/3 tyrosine kinase fusions define a unique molecular subtype of non-small cell lung cancer

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4741453

Large-cell neuroendocrine carcinoma of the lung harboring EGFR mutation and responding to gefitinib.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4741453

Comprehensive Analysis of Oncogenic Mutations in Lung Squamous Cell Carcinoma With Minor Glandular Component

21 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26486077

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.18632/ONCOTARGET.5549

1 reference

14 August 2017

1 reference

14 August 2017

PubMed publication ID

26486077

1 reference